Madrigal and Corcept Pharmaceuticals Compared in New Analysis

Analysts weigh the merits of these two mid-cap medical companies

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

A new report compares the performance and prospects of Madrigal Pharmaceuticals (NASDAQ:MDGL) and Corcept Therapeutics (NASDAQ:CORT), two mid-cap pharmaceutical companies with different drug development pipelines. The analysis looks at factors like revenue, earnings, valuation, volatility, analyst ratings, and institutional ownership to determine which stock is the better investment.

Why it matters

As mid-cap pharmaceutical companies, Madrigal and Corcept are competing for investor attention and capital. Understanding how they stack up on key metrics can help investors make more informed decisions about allocating their portfolios.

The details

The analysis finds that Corcept Therapeutics has higher earnings but lower revenue compared to Madrigal Pharmaceuticals. However, Madrigal trades at a lower price-to-earnings ratio, indicating it is currently the more affordable of the two stocks. In terms of volatility, Corcept has a beta of 0.29, making its share price 71% less volatile than the S&P 500, while Madrigal has a beta of -0.97, making its share price 197% less volatile. Analysts are more bullish on Corcept, with a consensus price target implying 128% potential upside, compared to 58% for Madrigal.

  • The report was published on March 8, 2026.

The players

Corcept Therapeutics

A pharmaceutical company that develops drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders.

Madrigal Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH).

Got photos? Submit your photos here. ›

The takeaway

This analysis provides a detailed comparison of two mid-cap pharmaceutical companies, highlighting their relative strengths and weaknesses across key financial and operational metrics. Investors looking to gain exposure to the pharmaceutical sector may find this information useful in evaluating Corcept Therapeutics and Madrigal Pharmaceuticals as potential investment options.